DHB Fundamental Analysis - DELIVRA HEALTH BRANDS INC

Name: DELIVRA HEALTH BRANDS INC (DHB) Stock
Brand: DELIVRA HEALTH BRANDS INC
Rating: 7 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to DHB. DHB was compared to 31 industry peers in the Pharmaceuticals industry. DHB has a bad profitability rating. Also its financial health evaluation is rather negative. DHB is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

DHB had negative earnings in the past year.

In the past year DHB has reported a negative cash flow from operations.

DHB had negative earnings in 4 of the past 5 years.

DHB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -12.42%, DHB perfoms like the industry average, outperforming 41.94% of the companies in the same industry.

With a Return On Equity value of -28.14%, DHB perfoms like the industry average, outperforming 45.16% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-12.42%
ROE	-28.14%
ROIC	N/A

ROA(3y)-1.81%

ROA(5y)-43.05%

ROE(3y)-5.55%

ROE(5y)-101.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 50.22%, DHB is in the better half of the industry, outperforming 70.97% of the companies in the same industry.

In the last couple of years the Gross Margin of DHB has grown nicely.

DHB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	50.22%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.54%

GM growth 5Y20.78%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, DHB has about the same amount of shares outstanding.

Compared to 5 years ago, DHB has more shares outstanding

Compared to 1 year ago, DHB has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -18.07, we must say that DHB is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -18.07, DHB is not doing good in the industry: 90.32% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.43 indicates that DHB is not too dependend on debt financing.

The Debt to Equity ratio of DHB (0.43) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF	N/A
Altman-Z	-18.07

ROIC/WACCN/A

WACC7.3%

2.3 Liquidity

A Current Ratio of 2.69 indicates that DHB has no problem at all paying its short term obligations.

DHB's Current ratio of 2.69 is fine compared to the rest of the industry. DHB outperforms 77.42% of its industry peers.

A Quick Ratio of 1.91 indicates that DHB should not have too much problems paying its short term obligations.

DHB has a better Quick ratio (1.91) than 80.65% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.69
Quick Ratio	1.91

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for DHB have decreased strongly by -274.77% in the last year.

Looking at the last year, DHB shows a quite strong growth in Revenue. The Revenue has grown by 8.01% in the last year.

The Revenue has been growing by 11.44% on average over the past years. This is quite good.

EPS 1Y (TTM)-274.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-67.13%

Revenue 1Y (TTM)8.01%

Revenue growth 3Y17.99%

Revenue growth 5Y11.44%

Sales Q2Q%21.53%

3.2 Future

The Earnings Per Share is expected to grow by 49.00% on average over the next years. This is a very strong growth

DHB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.79% yearly.

EPS Next Y80%

EPS Next 2Y49%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year13.99%

Revenue Next 2Y13.79%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DHB. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DHB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DHB is on the same level as its industry peers.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	24.42

4.3 Compensation for Growth

A more expensive valuation may be justified as DHB's earnings are expected to grow with 49.00% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y49%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

DHB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DELIVRA HEALTH BRANDS INC

TSX-V:DHB (11/12/2025, 7:00:00 PM)

0.34

+0.02 (+6.25%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)10-06 2025-10-06

Earnings (Next)11-24 2025-11-24

Inst Owners1.86%

Inst Owner ChangeN/A

Ins Owners13.09%

Ins Owner ChangeN/A

Market Cap10.63M

Revenue(TTM)13.37M

Net Income(TTM)-1.19M

Analysts84.44

Price Target0.73 (114.71%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.79
P/FCF	N/A
P/OCF	N/A
P/B	2.51
P/tB	2.51
EV/EBITDA	24.42

EPS(TTM)-0.04

EYN/A

EPS(NY)-0.01

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0.43

BVpS0.14

TBVpS0.14

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.42%
ROE	-28.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	50.22%
FCFM	N/A

ROA(3y)-1.81%

ROA(5y)-43.05%

ROE(3y)-5.55%

ROE(5y)-101.64%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.54%

GM growth 5Y20.78%

F-Score2

Asset Turnover1.39

Health

		Industry Rank	Sector Rank
Debt/Equity	0.43
Debt/FCF	N/A
Debt/EBITDA	5
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.69
Quick Ratio	1.91
Altman-Z	-18.07

F-Score2

WACC7.3%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-274.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-67.13%

EPS Next Y80%

EPS Next 2Y49%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.01%

Revenue growth 3Y17.99%

Revenue growth 5Y11.44%

Sales Q2Q%21.53%

Revenue Next Year13.99%

Revenue Next 2Y13.79%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-95.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year212.7%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-199.73%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-199.73%

OCF growth 3YN/A

OCF growth 5YN/A

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DHB.CA.

What is the valuation status of DELIVRA HEALTH BRANDS INC (DHB.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to DELIVRA HEALTH BRANDS INC (DHB.CA). This can be considered as Overvalued.

What is the profitability of DHB stock?

DELIVRA HEALTH BRANDS INC (DHB.CA) has a profitability rating of 2 / 10.

Can you provide the financial health for DHB stock?

The financial health rating of DELIVRA HEALTH BRANDS INC (DHB.CA) is 3 / 10.

DELIVRA HEALTH BRANDS INC (DHB.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DELIVRA HEALTH BRANDS INC / DHB.CA FAQ

Can you provide the ChartMill fundamental rating for DELIVRA HEALTH BRANDS INC?

What is the valuation status of DELIVRA HEALTH BRANDS INC (DHB.CA) stock?

What is the profitability of DHB stock?

Can you provide the financial health for DHB stock?